过氧化物酶体增殖激活物受体-γ在肾细胞癌中的表达及其意义  

Expression of Peroxisome Proliferator-actived Receptor Y in Renal Cell Carcinoma

作　　者：杨风光[1] 师长进[1] 张志文[2] 郭应禄[1] 吴阶平[1] 

机构地区：[1]北京大学第一医院泌尿外科北京大学泌尿外科研究所,100034 [2]北京大学医学部生理系

出　　处：《中华实验外科杂志》2004年第9期1107-1108,F003,共3页Chinese Journal of Experimental Surgery

摘　　要：目的观察过氧化物酶体增殖激活物受体(PPAR)-γ在肾细胞癌中的表达,探讨其意义.方法应用逆转录聚合酶链反应(RT-PCR)、免疫组织化学和Western blot从RNA及蛋白水平检测正常肾组织、肾癌组织和肾细胞株HK-2、HMCC;肾癌细胞株786-O、A498中PPAR-γ表达.结果肾癌组织、肾组织及细胞株中PPAR-γ mRNA普遍表达,肾癌中PPAR-γ蛋白表达量为正常肾的7.0～10.7倍;肾癌组织PPAR-γ阳性率为98.3%,肾组织中为60.0%,其表达强度差异有显著性(t=7.888,P＜0.01).PPAR-γ在肾癌的细胞核和细胞质中均表达;PPAR-γ表达和肾癌的分级、分期明显相关.结论核内受体PPAR-γ在人肾癌组织及肾癌细胞株中呈上调表达,提示PPAR-γ基因的激活可能是肾细胞癌治疗的一种新的方法.Objective To investigate the expression of peroxisome proliferator-actived receptor γ (PPAR-7) in renal cell carcinoma and to evaluate its possible significance. Methods The expression of PPAR-y mRNA and protein was detected in NK (normal kidney) tissues, RCC (renal cell carcinoma) tissues, two RCC-derived cell lines (786-O and A498) and two NK-derived cell lines HK-2 and HMCC by using RT-PCR and Western blot analysis. Immunohistochemistry was performed on specimens from 120 patients with RCC and from 20 NK tissues to examine the expression and localization of PPAR-γ. Results PPAR-γmRNA was expressed in all NK, RCC tissues, two RCC cell lines and two NK cell lines. The level of PPAR-γ protein was about 7.0-10.7 folds in RCC compared to NK by Western blot analysis. Immuno-histochemical study showed that PPAR-7was markedly increased in renal cell carcinoma tissues (t = 7.888, P <0.01)with overall positive rate of 98.3 % . PPAR-γ was strongly expressed in the perinuclear and cytoplasmic regions in RCC tissues. PPAR-γ expression was correlated with the stage and grade of RCC. Conclusion The expression of PPAR γ is stronger in RCC than in NK. PPAR-γ may play a role in the pathogenesis and progression of RCC. Actived PPAR-γ may he a novel approach to the treatment of this refractory neoplasm.

关 键 词：PPAR-Γ 表达 肾癌组织 肾细胞癌 受体 肾组织 激活 过氧化物酶体 RNA 细胞核 

分 类 号：R737.11[医药卫生—肿瘤] R734.2[医药卫生—临床医学]